Lipid Luminations

What's the evidence for LDL and other non-HDL targets for primary and secondary prevention of heart disease? What are the comparative benefits versus toxicities of all lipid-lowering medications in clinical use? Addressing these and other questions from the standpoing of recent NLA recommendations is Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL.

What are some of the causes of high triglycerides? What is the biggest health risk? And, for these patients, at what level is the risk greater for developing pancreatitis and coronary artery disease? Host Dr. Alan Brown welcomes Dr. Carl Orringer, Associate Professor of Medicine at the Cardiology Division, University of Miami Medical Center and Director of the Preventive Cardiovascular Medicine and LDL apheresis program. In this edition of Lipid Luminations, Dr. Orringer will discuss the management of the patients with triglycerides 200-499 mg/dl.

At the most recent National Lipid Association (NLA) meeting, host Dr. Alan Brown welcomes Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty position in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL. Drs. Brown and Maki discuss the evidence of the relationship of statin use and risk of new onset of diabetes; as well as, the relationship of statin use and the possiblity of worsening glycemia in those patients who have diabetes. What are the conclusions? What should clinicians be screening for?

Download and listen to this great conversation!

Host Dr. Alan Brown is joined by Anne Goldberg, MD, Associate Professor of Medicine at Washington University School of Medicine and a member of the ACC/AHA Blood Cholesterol Guidelines Panel. Dr. Goldberg will provide a review of the panel assembled by National Heart, Lung, and Blood Institute to construct integrated guidelines for cardiovascular risk reduction. She will also address the controversy regarding the ACC/AHA recently published risk assessment and cholesterol guidelines.

Download and listen today!

Host Dr. Alan Brown is joined by an expert panel to discuss the NLA's latest draft document that will serve as recommendations to clinicians for the management of patients with dyslipidemia. The National Lipid Association's goal was to harmonize guidelines among what has been presented in the past by the ATP panel, the American College of Cardiology/American Heart Association Guidelines, and those also released in 2013 by the International Atherosclerosis Society. The NLA reaffirms the importance of understanding targets of treatment and goals for patients.

Our expert panelists:

• Harold Bays, MD, FNLA - Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center; co-author of the National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia and co-author of the American Society of Bariatric Physicians Obesity Algorithm
  
• Matthew Ito, PharmD, FNLA - Professor of Pharmacy Practice and Director of the Cardiovascular Pharmacodynamics Laboratory at Oregon State University/Oregon Health & Science University; member of the National Lipid Association Expert Panel on the Diagnosis and Treatment of Familial Hypercholesterolemia and the Recommendations for Patient-Centered Management of Dyslipidemia
  
• Carl E. Orringer, MD, FACC, FNLA - Associate Professor of Medicine, Cardiology Division at the University of Miami Medical Center; Editorial reviewer and faculty …

Is there a patient age at which statin therapy should be discontinued? Likewise, what does the current evidence tell us about initiating vs not initiating statin therapy in older patients? Joining Lipid Luminations to discuss these and other important questions is Dr. W. Virgil Brown, Charles Howard Candler Professor of Medicine Emeritus at Emory University School of Medicine in Atlanta, Georgia.

Joining host Dr. Alan Brown is Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology of the Division of Medicine-Endocrinology and Metabolism at Duke University School of Medicine. Their discussion will focus on data and results from HPS-2 THRIVE, a large-scale study comparing the use of statins and niacin versus statins alone. THRIVE stands for the Treatment of HDL to Reduce the Incidence of Vascular Events.

Health information technologies have evolved dramatically from simplistic documentation devices early on to sophisticated drivers of quality patient care today. This emergence is having a particularly positive effect on treatment for dyslipidemia. Joining host Dr. Alan Brown to reflect on a recent NLA manuscript of HIT's impact toward adherence to lipid therapy is Dr. Jerome Cohen, Emeritus Professor of Internal Medicine at Saint Louis University School of Medicine and Director of Preventative Cardiology Program at the Saint Louis University Health Sciences Center. Dr. Cohen has been active in cardiovascular research for more than two decades.

Host Dr. Alan Brown welcomes Dr. Marc Hamilton, Professor at Pennington Biomedical Research Center in Baton Rouge, LA. Their convesation focuses on the cardiometabolic consequences of lengthy sitting times, such as in people with "desk job careers."

Joining host Dr. Alan Brown is Michael B. Bottorff, Pharm.D., Professor and Chair in the Department of Pharmacy Practice at South College School of Pharmacy in Knoxville, Tennessee. Dr. Bottorff will be reviewing generic medications, from manufacturing processes to approval measures.